Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for … – PR Newswire (press release)
|
Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for …
PR Newswire (press release) … the world's leading eye care company, for use of its Aganocide(R) compounds in the eye, ear and sinus, and in contact lens solutions. … and more » |